Braidwell LP Invests $9.09 Million in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Braidwell LP acquired a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 483,300 shares of the company's stock, valued at approximately $9,091,000. Braidwell LP owned 3.20% of Jasper Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. BNP Paribas Financial Markets increased its position in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after buying an additional 1,698 shares during the period. American Century Companies Inc. boosted its position in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock valued at $322,000 after acquiring an additional 3,032 shares in the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $59,000. Fernwood Investment Management LLC raised its position in shares of Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock worth $995,000 after acquiring an additional 3,427 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its stake in shares of Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after purchasing an additional 3,873 shares during the period. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Trading Down 1.9 %

JSPR stock traded down $0.43 during midday trading on Friday, hitting $22.81. The company's stock had a trading volume of 66,623 shares, compared to its average volume of 174,979. The company has a market cap of $342.15 million, a PE ratio of -4.81 and a beta of 2.19. The firm's 50-day moving average is $20.23 and its 200-day moving average is $20.91. Jasper Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $31.01.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on JSPR shares. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $70.00 to $68.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 14th. Evercore ISI restated an "outperform" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. JMP Securities reiterated a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics currently has an average rating of "Buy" and a consensus price target of $74.86.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.